首页> 外文期刊>Clinical pharmacokinetics >What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review
【24h】

What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review

机译:需要哪种抗生素暴露来抑制革兰氏阴性细菌的抗性的出现? 系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

Background The rates of antibiotic resistance in Gram-negative bacteria are increasing. One method to minimize resistance emergence may be optimization of antibiotic dosing regimens to achieve drug exposure that suppress the emergence of resistance. Objective The aim of this systematic review was to describe the antibiotic exposures associated with suppression of the emergence of resistance for Gram-negative bacteria. Methods We conducted a search of four electronic databases. Articles were included if the antibiotic exposure required to suppress the emergence of resistance in a Gram-negative bacterial isolate was described. Among studies, 57 preclinical studies (in vitro and in vivo) and 2 clinical studies 59 included investigated the monotherapy of antibiotics against susceptible and/or intermediate Gram-negative bacteria. Results The pharmacokinetic/pharmacodynamic (PK/PD) indices reported to suppress the emergence of antibiotic resistance for various classes were beta-lactam antibiotic minimum concentration to minimum inhibitory concentration (C-min/MIC) >= 4; aminoglycoside maximum concentration to MIC (C-max/MIC) ratio >= 20; fluoroquinolones, area under the concentration-time curve from 0 to 24 h to mutant prevention concentration (AUC(24)/MPC) >= 35; tetracyclines, AUC(24) to MIC (AUC(24)/MIC) ratio >= 50; polymyxin B, AUC(24)/MIC >= 808; and fosfomycin, AUC(24)/MIC >= 3136. However, the exposures required to suppress the emergence of resistance varied depending on the specific antibiotic tested, the duration of the experiment, the bacterial species and the specific bacterial isolate tested. Importantly, antibiotic exposures required to suppress the emergence of resistance generally exceeded that associated with clinical efficacy. Conclusion The benefits of implementing such high PK/PD targets must be balanced with the potential risks of antibiotic-associated toxicity.
机译:背景技术革兰氏阴性细菌中的抗生素抗性的速率正在增加。一种最小化抗性出现的方法可以是抗生素给药方案的优化,以实现抑制抗性出现的药物暴露。目的对这种系统审查的目的是描述与抑制革兰阴性细菌的抗性的抑制相关的抗生素暴露。方法我们进行了搜索四个电子数据库。如果描述了抑制革兰阴性细菌分离物中抗性的出现所需的抗生素暴露,则包括制品。在研究中,57项临床前研究(体外和体内)和2种临床研究59包括调查抗生素对敏感和/或中间革兰阴性细菌的单药治疗。结果据报道,抑制各种阶级抗生素抗性出现的药代动力学/药效学(PK / PD)指标是β-内酰胺抗生素最小浓度至最小抑制浓度(C-MIN / MIC)> = 4;氨基糖苷最大限度地浓度(C-MAX / MIC)比例> = 20;氟代喹啉,浓度 - 时间曲线下的面积为0至24小时,突变预防浓度(AUC(24)/ MPC)> = 35;四环素,AUC(24)至MIC(AUC(24)/ MIC)比例> = 50;多辛B,AUC(24)/ MIC> = 808;然而,AUC(24)/ MIC> = 3136.然而,抑制抗性出现所需的曝光根据特异性抗生素测试,实验的持续时间,细菌种类和测试的特异性细菌分离物。重要的是,抑制抗性所需的抗生素暴露通常超过与临床疗效相关的抗性。结论实施此类高PK / PD靶标的效益必须与抗生素相关毒性的潜在风险相平衡。

著录项

  • 来源
    《Clinical pharmacokinetics》 |2019年第11期|共37页
  • 作者单位

    Univ Queensland Sch Pharm Ctr Translat Antiinfect Pharmacodynam Brisbane Qld Australia;

    Univ Queensland Sch Pharm Ctr Translat Antiinfect Pharmacodynam Brisbane Qld Australia;

    Royal Brisbane &

    Womens Hosp Dept Intens Care Med Brisbane Qld Australia;

    Univ Queensland Sch Pharm Ctr Translat Antiinfect Pharmacodynam Brisbane Qld Australia;

    Univ Queensland Sch Pharm Ctr Translat Antiinfect Pharmacodynam Brisbane Qld Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号